A Double Standard in Practice: How American Corporations Export Environmental Compliance While Lobbying Against It at Home

There is a particular kind of cognitive dissonance embedded in the operations of several major American industrial corporations. In Frankfurt, Rotterdam, or Lyon, their facilities comply with rigorous chemical disclosure requirements, strict limits on occupational pesticide exposure, and mandatory environmental impact assessments that reflect decades of precautionary regulatory development. In Louisiana, Ohio, or North Carolina, the same parent companies — operating through the same legal entities, drawing on the same technical expertise — resist comparable requirements with organized legislative ferocity.

This is not a marginal or anecdotal phenomenon. It represents a coherent, if rarely articulated, corporate strategy: exploit the regulatory floor wherever it is lowest, while working to ensure it stays that way at home.

The Architecture of Regulatory Arbitrage

The term regulatory arbitrage is borrowed from financial economics, where it describes the practice of structuring transactions to exploit differences in regulatory treatment across jurisdictions. Applied to environmental and occupational health policy, the concept captures something more consequential: the deliberate calibration of corporate compliance behavior to the minimum standard that legal exposure in each jurisdiction requires, combined with political investment to prevent domestic standards from converging with more protective international norms.

The European Union's regulatory environment — shaped by the REACH chemical regulation framework, the Industrial Emissions Directive, and a constellation of sector-specific occupational health directives — imposes obligations on manufacturers that have no direct equivalent in US federal law. Under REACH, chemical manufacturers bear the burden of demonstrating that substances placed on the market are safe, rather than requiring regulators to prove harm before restricting use. This precautionary inversion, sometimes called the reverse onus, creates compliance costs that American companies operating in Europe absorb as a condition of market access.

The same companies, through their trade associations and direct lobbying operations in Washington, have consistently opposed the adoption of analogous frameworks domestically. The Lautenberg Chemical Safety for the 21st Century Act of 2016 reformed the Toxic Substances Control Act but retained a hazard-demonstration requirement that places the evidentiary burden on the EPA rather than on manufacturers — the precise inversion of the European model. Industry lobbying was central to preserving that asymmetry.

Chemical Manufacturing: The Clearest Case

The chemical sector provides the most extensively documented examples of this dynamic. Several compounds that have been restricted or banned outright under EU chemical regulations continue to be manufactured and used in the United States, in some cases at facilities operated by corporations whose European subsidiaries comply with the corresponding restrictions.

Chloropicrin, a soil fumigant with well-documented respiratory toxicity, is subject to strict occupational exposure limits and application restrictions across EU member states. In California's agricultural counties, exposure incidents among farmworkers remain a recurring public health concern, and federal occupational standards lag substantially behind European equivalents. The manufacturers of such compounds have not been passive bystanders in this regulatory gap; their trade associations have actively contested proposed EPA exposure limit reductions, citing economic disruption and disputing the underlying toxicological evidence — evidence that their own European regulatory filings have, in other contexts, implicitly accepted.

The case of certain per- and polyfluoroalkyl substances (PFAS) follows a similar pattern. Several major chemical manufacturers phased out specific long-chain PFAS formulations in Europe in advance of regulatory deadlines, while simultaneously contesting the scientific basis for equivalent US restrictions. The technical capacity to substitute safer alternatives evidently existed; the regulatory pressure to deploy it domestically did not.

Food Production and Agricultural Inputs

The food and agricultural sectors present equally instructive cases. The European Union has banned or severely restricted dozens of pesticide active ingredients that remain registered for use in the United States, including several that major American agribusiness firms sell in both markets under different product formulations. The disparity is not merely theoretical: epidemiological research linking certain organophosphate compounds to neurodevelopmental outcomes in children has informed EU restriction decisions while failing to produce equivalent federal regulatory responses in the US, in part because of sustained industry opposition to the underlying scientific interpretations.

Food additive and processing aid regulations reveal a similar divergence. Several synthetic dyes, preservatives, and processing chemicals permitted in US food manufacturing under FDA generally-recognized-as-safe (GRAS) designations are prohibited or require mandatory warning labels in the EU. American food manufacturers export products to European markets in formulations that differ from their domestic equivalents — substituting natural colorants for synthetic ones, for example — because EU market access requirements demand it. The domestic formulations, meanwhile, persist because there is no comparable regulatory compulsion to change them.

This is not a matter of differing scientific consensus in any straightforward sense. The same corporations possess the technical knowledge to produce the cleaner formulations; they do so routinely for export. The decision to maintain different standards for domestic consumers is, at its core, a business calculation enabled by regulatory environment, not a reflection of genuine scientific uncertainty.

Political Pathways and Their Consequences

The mechanisms through which corporations translate economic interest into legislative outcomes are well established in the political science literature. Trade associations — the American Chemistry Council, the American Farm Bureau Federation, the Grocery Manufacturers Association and its successor entities — aggregate member company interests and deploy them through campaign contributions, direct lobbying, participation in regulatory comment processes, and the funding of think-tank research that challenges the scientific basis for proposed regulations.

The consequences for American communities situated near major industrial facilities are not abstract. Environmental justice research consistently documents elevated rates of respiratory disease, certain cancers, and adverse birth outcomes in communities proximate to chemical manufacturing and intensive agricultural operations — communities that are disproportionately low-income and non-white. The regulatory standards that might attenuate these exposures are available; they exist and function in other wealthy democracies. Their absence in the US is not a product of scientific ignorance but of political economy.

Toward Regulatory Convergence

Addressing this structural asymmetry requires interventions at multiple levels. Strengthening the EPA's authority to require manufacturers to affirmatively demonstrate chemical safety — rather than bearing the burden of proving harm — would partially align domestic standards with European practice. Occupational Safety and Health Administration rulemaking on chemical exposure limits, which has proceeded at a pace charitably described as glacial, requires both statutory reinforcement and significantly expanded enforcement capacity.

At the trade policy level, the United States has periodic opportunities to incorporate environmental and health standard provisions into bilateral and multilateral agreements. Leveraging market access negotiations to establish minimum regulatory floors — rather than using trade frameworks to challenge foreign precautionary standards as non-tariff barriers — would reduce the arbitrage opportunity that currently structures corporate compliance behavior.

Transparency requirements also merit attention. Mandatory public disclosure of the regulatory standards applied at each corporate facility, disaggregated by jurisdiction, would allow investors, consumers, and affected communities to assess the gap between what companies do abroad and what they do at home. Sunlight, in this context, is not merely symbolic; it creates reputational and financial pressure that can move corporate behavior in advance of formal regulation.

Conclusion

The paradox at the center of this analysis is, in its way, clarifying. American corporations operating under Europe's environmental and occupational health standards are not crippled by the experience. They adapt, innovate, and remain profitable. The argument that equivalent domestic standards would be economically catastrophic is contradicted by the demonstrated capacity of the same companies to absorb those standards wherever regulators require them to.

What differs is not capability but compulsion. And the political effort invested in preventing that compulsion from materializing domestically — while quietly complying with it abroad — is itself a form of public health policy, with consequences borne disproportionately by American workers and communities who have the least capacity to advocate for themselves.